An Observational Study of RoActemra/Actemra (Tocilizumab) in Patients With Rheumatoid Arthritis Who Have an Inadequate Response to DMARDs

Update Il y a 4 ans
Reference: NCT01388309

Woman and Man

  • | Country :
  • Slovakia
  • | organs :
  • -
  • | Specialty :
  • -

Extract

This observational study will evaluate in clinical practice the change in Disease Activity Score (DAS28) in patients with rheumatoid arthritis and an inadequate response to DMARDs who are initiated on treatment with RoActemra/Actemra (tocilizumab). Data will be collected from eligible patients (on 8 mg/kg or 4 mg/kg intravenously every 4 weeks, with or without methotrexate) for 12 months.


Inclusion criteria

  • Rheumatoid Arthritis

Links